GlassScriptPhysician profile
Massimo R Gramanzini
NPI 1003968751
$3,585.17
in general payments reported to CMS, 2019-2025
11 companies · $600 in 2025
The $600 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $253 · 2021: $432 · 2022: $433 · 2023: $622 · 2024: $752 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,611.83 | 2022-2025 | Infuse, Infuse Multifocal, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $884.24 | 2019-2021 | |
| Glaukos Corporation | $324.38 | 2024-2025 | Idose, Kxl System (Not Refurbished) |
| Coopervision INC. | $191.10 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Mallinckrodt Hospital Products INC. | $130.63 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $130.30 | 2023 | Cequa |
| Optos, INC. | $96.77 | 2019 | |
| Allergan, INC. | $83.56 | 2021 | |
| Abb Con-Cise Optical Group LLC | $62.69 | 2019-2021 | |
| Genzyme Corporation | $50.00 | 2024 | |
| Rxsight INC | $19.67 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massimo Gramanzini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.